Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer

2.50
Hdl Handle:
http://hdl.handle.net/11287/593945
Title:
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Authors:
Zargar, H.; Espiritu, P. N.; Fairey, A. S.; Mertens, L. S.; Dinney, C. P.; Mir, M. C.; Krabbe, L. M.; Cookson, M. S.; Jacobsen, N. E.; Gandhi, N. M.; Griffin, J.; Montgomery, J. S.; Vasdev, N.; Yu, E. Y.; Youssef, D.; Xylinas, E.; Campain, Nick J.; Kassouf, W.; Dall'Era, M. A.; Seah, J. A.; Ercole, C. E.; Horenblas, S.; Sridhar, S. S.; McGrath, John S; Aning, J.; Shariat, S. F.; Wright, J. L.; Thorpe, A. C.; Morgan, T. M.; Holzbeierlein, J. M.; Bivalacqua, T. J.; North, S.; Barocas, D. A.; Lotan, Y.; Garcia, J. A.; Stephenson, A. J.; Shah, J. B.; van Rhijn, B. W.; Daneshmand, S.; Spiess, P. E.; Black, P. C.
Abstract:
BACKGROUND: The efficacy of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (BCa) was established primarily with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), with complete response rates (pT0) as high as 38%. However, because of the comparable efficacy with better tolerability of gemcitabine and cisplatin (GC) in patients with metastatic disease, GC has become the most commonly used regimen in the neoadjuvant setting. OBJECTIVE: We aimed to assess real-world pathologic response rates to NAC with different regimens in a large, multicenter cohort. DESIGN, SETTING, AND PARTICIPANTS: Data were collected retrospectively at 19 centers on patients with clinical cT2-4aN0M0 urothelial carcinoma of the bladder who received at least three cycles of NAC, followed by radical cystectomy (RC), between 2000 and 2013. INTERVENTION: NAC and RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was pathologic stage at cystectomy. Univariable and multivariable analyses were used to determine factors predictive of pT0N0 and </=pT1N0 stages. RESULTS AND LIMITATIONS: Data were collected on 935 patients who met inclusion criteria. GC was used in the majority of the patients (n=602; 64.4%), followed by MVAC (n=183; 19.6%) and other regimens (n=144; 15.4%). The rates of pT0N0 and </=pT1N0 pathologic response were 22.7% and 40.8%, respectively. The rate of pT0N0 disease for patients receiving GC was 23.9%, compared with 24.5% for MVAC (p=0.2). There was no difference between MVAC and GC in pT0N0 on multivariable analysis (odds ratio: 0.89 [95% confidence interval, 0.61-1.34]; p=0.6). CONCLUSIONS: Response rates to NAC were lower than those reported in prospective randomized trials, and we did not discern a difference between MVAC and GC. Without any evidence from randomized prospective trials, the best NAC regimen for invasive BCa remains to be determined. PATIENT SUMMARY: There was no apparent difference in the response rates to the two most common presurgical chemotherapy regimens for patients with bladder cancer.
Citation:
Eur Urol. 2015 Feb;67(2):241-9.
Publisher:
Elsevier
Journal:
European urology
Issue Date:
1-Feb-2015
URI:
http://hdl.handle.net/11287/593945
DOI:
10.1016/j.eururo.2014.09.007
PubMed ID:
25257030
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0302-2838(14)00893-8
Type:
Journal Article; Research Support, Non-U.S. Gov't
Language:
eng
ISSN:
1873-7560
Appears in Collections:
2015 RD&E publications; Urology; HeSRU publications

Full metadata record

DC FieldValue Language
dc.contributor.authorZargar, H.en
dc.contributor.authorEspiritu, P. N.en
dc.contributor.authorFairey, A. S.en
dc.contributor.authorMertens, L. S.en
dc.contributor.authorDinney, C. P.en
dc.contributor.authorMir, M. C.en
dc.contributor.authorKrabbe, L. M.en
dc.contributor.authorCookson, M. S.en
dc.contributor.authorJacobsen, N. E.en
dc.contributor.authorGandhi, N. M.en
dc.contributor.authorGriffin, J.en
dc.contributor.authorMontgomery, J. S.en
dc.contributor.authorVasdev, N.en
dc.contributor.authorYu, E. Y.en
dc.contributor.authorYoussef, D.en
dc.contributor.authorXylinas, E.en
dc.contributor.authorCampain, Nick J.en
dc.contributor.authorKassouf, W.en
dc.contributor.authorDall'Era, M. A.en
dc.contributor.authorSeah, J. A.en
dc.contributor.authorErcole, C. E.en
dc.contributor.authorHorenblas, S.en
dc.contributor.authorSridhar, S. S.en
dc.contributor.authorMcGrath, John Sen
dc.contributor.authorAning, J.en
dc.contributor.authorShariat, S. F.en
dc.contributor.authorWright, J. L.en
dc.contributor.authorThorpe, A. C.en
dc.contributor.authorMorgan, T. M.en
dc.contributor.authorHolzbeierlein, J. M.en
dc.contributor.authorBivalacqua, T. J.en
dc.contributor.authorNorth, S.en
dc.contributor.authorBarocas, D. A.en
dc.contributor.authorLotan, Y.en
dc.contributor.authorGarcia, J. A.en
dc.contributor.authorStephenson, A. J.en
dc.contributor.authorShah, J. B.en
dc.contributor.authorvan Rhijn, B. W.en
dc.contributor.authorDaneshmand, S.en
dc.contributor.authorSpiess, P. E.en
dc.contributor.authorBlack, P. C.en
dc.date.accessioned2016-01-19T12:37:49Zen
dc.date.available2016-01-19T12:37:49Zen
dc.date.issued2015-02-01en
dc.identifier.citationEur Urol. 2015 Feb;67(2):241-9.en
dc.identifier.issn1873-7560en
dc.identifier.pmid25257030en
dc.identifier.doi10.1016/j.eururo.2014.09.007en
dc.identifier.urihttp://hdl.handle.net/11287/593945en
dc.description.abstractBACKGROUND: The efficacy of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (BCa) was established primarily with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), with complete response rates (pT0) as high as 38%. However, because of the comparable efficacy with better tolerability of gemcitabine and cisplatin (GC) in patients with metastatic disease, GC has become the most commonly used regimen in the neoadjuvant setting. OBJECTIVE: We aimed to assess real-world pathologic response rates to NAC with different regimens in a large, multicenter cohort. DESIGN, SETTING, AND PARTICIPANTS: Data were collected retrospectively at 19 centers on patients with clinical cT2-4aN0M0 urothelial carcinoma of the bladder who received at least three cycles of NAC, followed by radical cystectomy (RC), between 2000 and 2013. INTERVENTION: NAC and RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was pathologic stage at cystectomy. Univariable and multivariable analyses were used to determine factors predictive of pT0N0 and </=pT1N0 stages. RESULTS AND LIMITATIONS: Data were collected on 935 patients who met inclusion criteria. GC was used in the majority of the patients (n=602; 64.4%), followed by MVAC (n=183; 19.6%) and other regimens (n=144; 15.4%). The rates of pT0N0 and </=pT1N0 pathologic response were 22.7% and 40.8%, respectively. The rate of pT0N0 disease for patients receiving GC was 23.9%, compared with 24.5% for MVAC (p=0.2). There was no difference between MVAC and GC in pT0N0 on multivariable analysis (odds ratio: 0.89 [95% confidence interval, 0.61-1.34]; p=0.6). CONCLUSIONS: Response rates to NAC were lower than those reported in prospective randomized trials, and we did not discern a difference between MVAC and GC. Without any evidence from randomized prospective trials, the best NAC regimen for invasive BCa remains to be determined. PATIENT SUMMARY: There was no apparent difference in the response rates to the two most common presurgical chemotherapy regimens for patients with bladder cancer.en
dc.language.isoengen
dc.publisherElsevieren
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0302-2838(14)00893-8en
dc.titleMulticenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder canceren
dc.typeJournal Articleen
dc.typeResearch Support, Non-U.S. Gov'ten
dc.identifier.journalEuropean urologyen

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.